TAUNS LaboratoriesTAUNS Laboratories, Inc.197A東証スタンダード医薬品FY ending Jun 2026, non-consolidated, J-GAAP
Out of every ¥100 of sales, about ¥29 is left as operating profit. Revenue changed -22.9% from the prior year, operating profit -49.2%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2023 | 19.4% | 0.85× | 16.6% | 2.16× | 35.8% |
| 2024 | 31.3% | 0.77× | 24.3% | 2.15× | 52.1% |
| 2025 | 33.9% | 0.57× | 19.2% | 2.12× | 40.7% |
| 2026 | 38.2% | 0.35× | 13.5% | 2.21× | 29.9% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Jun 2023 | FY ending Jun 2024 | FY ending Jun 2025 | FY ending Jun 2026 |
|---|---|---|---|---|
| Revenue | 15,673 | 18,435 | 18,628 | 14,369 |
| Cost of revenue | 6,473 | 5,937 | 5,853 | 5,548 |
| Gross profit | 9,200 | 12,498 | 12,775 | 8,821 |
| SG&A | 4,233 | 4,468 | 4,510 | 4,621 |
| Operating income | 4,967 | 8,030 | 8,265 | 4,200 |
| Pretax income | 4,655 | 7,835 | 8,202 | 7,896 |
| Income tax | 1,620 | 2,061 | 1,886 | 2,400 |
| Net income attributable to owners | 3,035 | 5,774 | 6,315 | 5,495 |
| Operating margin | 31.7% | 43.6% | 44.4% | 29.2% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Jun 2023 | FY ending Jun 2024 | FY ending Jun 2025 | FY ending Jun 2026 |
|---|---|---|---|---|
| Cash and equivalents | ¥1.24B | ¥9.42B | ¥9.27B | ¥3.56B |
| Total assets | ¥18.3B | ¥29.3B | ¥36.5B | ¥44.6B |
| Net assets | ¥8.49B | ¥13.7B | ¥17.4B | ¥19.4B |
| Share capital | ¥100M | ¥200M | ¥289.8M | ¥400.8M |
| Property, plant and equipment | ¥4.4B | ¥7.91B | ¥12.3B | ¥15.2B |
| Intangible assets excluding goodwill | ¥3.91B | ¥3.72B | ¥3.84B | ¥3.59B |
| Investment securities | ¥32.5M | ¥33.3M | ¥4.18B | ¥6.08B |
| Current assets | ¥9.46B | ¥16.9B | ¥15.5B | ¥19.3B |
| Current liabilities | ¥6.52B | ¥10.5B | ¥9.53B | ¥15.3B |
| Short-term borrowings | ¥3.5B | ¥4.5B | ¥4.5B | ¥7.5B |
| Long-term borrowings | ¥2.24B | ¥4.31B | ¥8.81B | ¥8.03B |
| Total liabilities | ¥9.84B | ¥15.6B | ¥19.1B | ¥25.2B |
| Equity attributable to owners of parent | ¥8.49B | ¥13.7B | ¥17.4B | ¥19.3B |
| Retained earnings | ¥5.6B | ¥10.8B | ¥14.3B | ¥16B |
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.